Advances in Oral Oncology: The 2025 Framework
This one hour seminar will address key components of contemporary, evidence-based oral oncology clinical practice based on high-quality guidelines as published in ASCO’s Journal of Clinical Oncology and related oncology journals. Discussion will include prevention and treatment of oral adverse events in oncology patients, including oral mucosal injury caused by cancer therapies, medication-related osteonecrosis of the jaw, salivary hypofunction caused by non-surgical cancer therapies, and osteoradionecrosis. The role of dental professionals in inter-professional oncology management will be highlighted, as well as future research directions.
*You may attend this course in person, or over zoom.
Click here to Register You will be directed to the University of Pittsburgh School of Dental Medicine.
Learning Objectives
- Illustrate the role of oral oncology in interprofessional oncology patient care and survivorship
- Highlight the integration of recent key research advances with high quality oral oncology guidelines
- Delineate opportunities for novel interdisciplinary research that in turn could further enhance management of oncology patients in the future.
Douglas E. Peterson, DMD, Ph.D, FDS RCSEd, FASCO
Dr. Peterson has contributed to oral oncology research, clinical practice, and interprofessional education for over four decades. Among many roles, he has been an oral oncology advocate with the American Society of Clinical Oncology (ASCO), which is comprised of more than 50,000 oncology professionals representing more than 150 countries. He is the first dental degree holder to have both chaired ASCO’s Clinical Practice Guideline Committee, as well as having received ASCO’s Fellowship Award (FASCO) for extraordinary volunteer service, engagement, and dedication to ASCO.
Additional recognition includes his receiving the FDS RCSEd without Examination from the Royal College of Surgeons/Edinburgh, and most recently the Outstanding Publication Award from the Multinational Association of Supportive Care in Cancer in 2024.
Conflict of Interest Disclosure
No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
CME Accreditation and Credit Designation
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician (CME)
The University of Pittsburgh designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Conflict of Interest Disclosure
No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 1.00 Attendance
*You may attend this course in person, or over zoom.
Click here to Register You will be directed to the University of Pittsburgh School of Dental Medicine.